Stress Echocardiography: the Role in Assessing Valvular Heart Diseases
Purpose of Review
Stress echocardiography (SE) has clinical utility beyond its conventional use for the evaluation of myocardial ischemia. More specifically, SE has been shown to have significant clinical value in patients with valvular heart disease (VHD), hypertrophic cardiomyopathy (HCM), and congenital heart disease (CHD). Echocardiography laboratories providing services to such patient should be familiar with the principals of SE beyond coronary artery disease to ensure its optimum application and performance.
The increased demand for SE standardization specifically in patients with VHD instigated recent recommendations by relevant cardiology societies.
This manuscript reviews the key concepts in performance and interpretation of hemodynamic SE in patients with VHD and HCM, including patient selection, stress modality of choice, and integration of all diagnostic and prognostic information.
KeywordsValvular heart disease Stress echocardiography Hypertrophic cardiomyopathy
American College of Cardiology
American Heart Association
European Association for Cardio-Thoracic Surgery
European Society of Cardiology
Left ventricle outflow tract
Pulmonary artery systolic pressure
Compliance with Ethical Standards
Conflict of Interest
All authors declare no conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.• Lancellotti P, Budtts C et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. 2017;30(2):101–138. Evidence-based recommendation from the ASE and EACVI for the use of echo in non-ischemic heart disease. Google Scholar
- 5.Lowenstein JA, Caniggia C, Rousse G, Amor M, Sanchez ME, Alasia D, et al. Coronary flow velocity reserve during pharmacologic stress echocardiography with normal contractility adds important prognostic value in diabetic and nondiabetic patients. J Am Soc Echocardiogr. 2014;27:1113–9.CrossRefGoogle Scholar
- 11.Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:e57–185.CrossRefGoogle Scholar
- 13.• Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89 Evidence-based recommendation from the AHA/ACC for the management of valvular heart disease. CrossRefGoogle Scholar
- 16.Cheitlin MD. Stress echocardiography in mitral stenosis: when is it useful? J Am Coll Cardiol. United States, 2004;402–4.Google Scholar
- 23.Verseckaite R, Mizariene V, Montvilaite A et al. The predictive value of left ventricular myocardium mechanics evaluation in asymptomatic patients with aortic regurgitation and preserved left ventricular ejection fraction. A long-term speckle-tracking echocardiographic study. Echocardiography. 2018.Google Scholar
- 29.Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995;92:785–9.CrossRefGoogle Scholar
- 32.• Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:e783–831 Evidence-based recommendation from the ACCF/AHA for the management of hypertrophic cardiomyopathy. PubMedGoogle Scholar
- 33.• Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79 Evidence-based recommendation from the ESC for the management of hypertrophic cardiomyopathy. CrossRefGoogle Scholar
- 36.Prasad M, Geske JB, Sorajja P, Ommen SR, Schaff HV, Gersh BJ, et al. Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction. Catheter Cardiovasc Interv. 2016;88:962–70.CrossRefGoogle Scholar
- 38.Tower-Rader A, Betancor J, Popovic ZB, Sato K, Thamilarasan M, Smedira NG, et al. Incremental prognostic utility of left ventricular global longitudinal strain in hypertrophic obstructive cardiomyopathy patients and preserved left ventricular ejection fraction. J Am Heart Assoc. 2017;6.Google Scholar
- 40.Fujimoto K, Inoue K, Saito M et al. Incremental value of left atrial active function measured by speckle tracking echocardiography in patients with hypertrophic cardiomyopathy. Echocardiography. 2018.Google Scholar